Laufman LR - Search Results

1

Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.

Sondak VK, Kopecky KJ, Liu PY, Fletcher WS, Harvey WH, Laufman LR. Sondak VK, et al. Among authors: laufman lr. Anticancer Drugs. 1994 Apr;5(2):147-50. Anticancer Drugs. 1994. PMID: 8049497 Clinical Trial.

2

Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study.

Cain JM, Liu PY, Alberts DE, Gallion HH, Laufman L, O'Sullivan J, Weiss G, Bickers JN. Cain JM, et al. Invest New Drugs. 1992 Apr;10(1):23-4. doi: 10.1007/BF01275473. Invest New Drugs. 1992. PMID: 1607250 Clinical Trial.

3

Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group.

Grozea PN, Crowley JJ, Canfield VA, Kingsbury L, Ross SW, Beltran GS, Laufman LR, Weiss GR, Livingston RB. Grozea PN, et al. Among authors: laufman lr. Cancer. 1997 Sep 15;80(6):1029-33. Cancer. 1997. PMID: 9305702 Clinical Trial.

4

VM-26 in gastric cancer. A Southwest Oncology Group study.

Berenberg JL, Tangen C, Macdonald JS, Barlogie B, Laufman LR. Berenberg JL, et al. Among authors: laufman lr. Invest New Drugs. 1993 Nov;11(4):333-4. doi: 10.1007/BF00874433. Invest New Drugs. 1993. PMID: 8157475 Clinical Trial.

5

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.

Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD. Dalton WS, et al. Among authors: laufman lr. Cancer. 1995 Feb 1;75(3):815-20. doi: 10.1002/1097-0142(19950201)75:3<815::aid-cncr2820750311>3.0.co;2-r. Cancer. 1995. PMID: 7828131 Clinical Trial.

6

VM-26 in colorectal carcinoma: a Southwest Oncology Group study.

Oishi N, Fleming TR, Laufman L, Ungerleider JS, Natale RB, Einstein AB Jr, Von Hoff DD, Macdonald JS. Oishi N, et al. Invest New Drugs. 1990 Feb;8(1):93-5. doi: 10.1007/BF00216931. Invest New Drugs. 1990. PMID: 2188930 Free article. Clinical Trial.

7

A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.

Spiridonidis CH, Laufman LR, Jones JJ, Gray DJ, Cho CC, Young DC. Spiridonidis CH, et al. Among authors: laufman lr. Cancer. 1996 Nov 15;78(10):2070-7. Cancer. 1996. PMID: 8918399 Clinical Trial.

8

Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.

Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA, Salmon SE. Kraut EH, et al. Among authors: laufman lr. J Clin Oncol. 1998 Feb;16(2):589-92. doi: 10.1200/JCO.1998.16.2.589. J Clin Oncol. 1998. PMID: 9469346

9

Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.

Neidhart JA, Laufman LR, Vaughn C, McCracken JD. Neidhart JA, et al. Among authors: laufman lr. Cancer Treat Rep. 1980 Apr-May;64(4-5):675-7. Cancer Treat Rep. 1980. PMID: 7427953

10

Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.

Panettiere FJ, Goodman PJ, Costanzi JJ, Cruz AB Jr, Vaitkevicius VK, McCracken JD, Brownlee RW, Laufman L, Stephens RL, Bonnet J, et al. Panettiere FJ, et al. J Clin Oncol. 1988 Jun;6(6):947-54. doi: 10.1200/JCO.1988.6.6.947. J Clin Oncol. 1988. PMID: 3286830 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page